Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACLX |
---|---|---|
09:32 ET | 77549 | 85.37 |
09:34 ET | 700 | 84.67 |
09:36 ET | 1350 | 84.55 |
09:38 ET | 700 | 83.98 |
09:39 ET | 1218 | 83.98 |
09:41 ET | 200 | 84.21 |
09:43 ET | 1000 | 84.685 |
09:45 ET | 600 | 84.71 |
09:48 ET | 13975 | 86.4399 |
09:50 ET | 10602 | 85.69 |
09:52 ET | 7014 | 85.72 |
09:54 ET | 3233 | 86.15 |
09:56 ET | 5800 | 86.1061 |
09:57 ET | 4464 | 86.5 |
09:59 ET | 5275 | 86.04 |
10:01 ET | 2416 | 86.1818 |
10:03 ET | 1045 | 86.54 |
10:06 ET | 665 | 86.11 |
10:08 ET | 1100 | 86.145 |
10:10 ET | 3217 | 86.295 |
10:12 ET | 1700 | 86.36 |
10:14 ET | 1056 | 85.54 |
10:15 ET | 3552 | 85.5 |
10:17 ET | 600 | 85.7 |
10:19 ET | 1602 | 86 |
10:21 ET | 200 | 85.935 |
10:24 ET | 500 | 86.02 |
10:26 ET | 100 | 86.02 |
10:28 ET | 920 | 86.72 |
10:30 ET | 1081 | 86.85 |
10:32 ET | 349 | 86.835 |
10:33 ET | 65304 | 86.634 |
10:35 ET | 879 | 86.28 |
10:37 ET | 1150 | 86.11 |
10:39 ET | 1594 | 86.515 |
10:42 ET | 1494 | 86.59 |
10:44 ET | 300 | 86.62 |
10:46 ET | 300 | 86.565 |
10:48 ET | 300 | 86.5 |
10:50 ET | 2389 | 86.63 |
10:51 ET | 900 | 87.06 |
10:53 ET | 200 | 86.935 |
10:55 ET | 2641 | 87.68 |
10:57 ET | 500 | 87.64 |
11:00 ET | 1492 | 87.61 |
11:02 ET | 900 | 87.34 |
11:04 ET | 900 | 87.12 |
11:06 ET | 11317 | 87.33 |
11:08 ET | 1100 | 87.27 |
11:09 ET | 14805 | 88.015 |
11:11 ET | 10783 | 87.26 |
11:13 ET | 807 | 87.155 |
11:15 ET | 700 | 87.105 |
11:18 ET | 2502 | 86.7 |
11:20 ET | 1000 | 87.03 |
11:22 ET | 3600 | 87.174 |
11:24 ET | 1400 | 86.795 |
11:26 ET | 1752 | 87.11 |
11:27 ET | 1329 | 87.47 |
11:29 ET | 600 | 87.46 |
11:31 ET | 1200 | 87.3 |
11:33 ET | 2938 | 87.25 |
11:36 ET | 2573 | 87.61 |
11:38 ET | 1528 | 87.75 |
11:40 ET | 3421 | 88.14 |
11:42 ET | 1502 | 87.83 |
11:44 ET | 2301 | 87.805 |
11:45 ET | 2152 | 87.74 |
11:47 ET | 945 | 87.725 |
11:49 ET | 1267 | 87.87 |
11:51 ET | 1371 | 87.71 |
11:54 ET | 483 | 87.68 |
11:56 ET | 500 | 87.78 |
11:58 ET | 400 | 87.99 |
12:00 ET | 1774 | 87.82 |
12:02 ET | 2214 | 87.73 |
12:03 ET | 575 | 87.9 |
12:05 ET | 955 | 88.1 |
12:07 ET | 403 | 88.17 |
12:09 ET | 1162 | 88.445 |
12:12 ET | 1000 | 88.3 |
12:14 ET | 1600 | 88.04 |
12:16 ET | 608 | 88.105 |
12:18 ET | 764 | 87.91 |
12:20 ET | 300 | 87.83 |
12:21 ET | 1000 | 87.875 |
12:23 ET | 305 | 87.865 |
12:25 ET | 1911 | 87.845 |
12:27 ET | 300 | 87.84 |
12:30 ET | 200 | 87.8 |
12:32 ET | 1513 | 88 |
12:34 ET | 602 | 87.89 |
12:36 ET | 200 | 88.01 |
12:38 ET | 700 | 87.8 |
12:39 ET | 700 | 87.545 |
12:41 ET | 1496 | 87.39 |
12:43 ET | 406 | 87.31 |
12:45 ET | 107 | 87.47 |
12:48 ET | 810 | 87.465 |
12:50 ET | 200 | 87.61 |
12:52 ET | 200 | 87.49 |
12:54 ET | 202 | 87.395 |
12:56 ET | 400 | 87.29 |
12:57 ET | 905 | 87.265 |
12:59 ET | 1796 | 87.425 |
01:01 ET | 200 | 87.47 |
01:03 ET | 105 | 87.47 |
01:06 ET | 400 | 87.22 |
01:08 ET | 304 | 87.345 |
01:10 ET | 1100 | 87.66 |
01:12 ET | 707 | 87.65 |
01:14 ET | 400 | 87.7 |
01:15 ET | 1150 | 87.5702 |
01:17 ET | 749 | 87.75 |
01:19 ET | 500 | 87.695 |
01:21 ET | 500 | 87.655 |
01:24 ET | 4408 | 87.17 |
01:26 ET | 678 | 87.14 |
01:28 ET | 500 | 87.175 |
01:30 ET | 900 | 87.15 |
01:32 ET | 400 | 86.7 |
01:33 ET | 300 | 86.89 |
01:35 ET | 100 | 86.86 |
01:37 ET | 656 | 86.85 |
01:39 ET | 3440 | 86.74 |
01:42 ET | 600 | 86.44 |
01:44 ET | 100 | 86.67 |
01:46 ET | 400 | 86.54 |
01:48 ET | 1635 | 86.565 |
01:50 ET | 400 | 86.48 |
01:51 ET | 1400 | 86.7 |
01:53 ET | 717 | 86.63 |
01:55 ET | 716 | 86.465 |
02:00 ET | 900 | 86.4 |
02:04 ET | 100 | 86.32 |
02:06 ET | 1029 | 86.14 |
02:08 ET | 935 | 86.3 |
02:09 ET | 425 | 86.41 |
02:11 ET | 426 | 86.23 |
02:13 ET | 569 | 86.28 |
02:15 ET | 400 | 86.455 |
02:18 ET | 1377 | 86.38 |
02:20 ET | 600 | 86.385 |
02:22 ET | 200 | 86.26 |
02:24 ET | 640 | 86.281 |
02:26 ET | 941 | 86.23 |
02:27 ET | 200 | 86.2 |
02:29 ET | 1600 | 86.18 |
02:31 ET | 450 | 85.94 |
02:33 ET | 1004 | 85.97 |
02:36 ET | 3197 | 85.62 |
02:38 ET | 200 | 85.64 |
02:40 ET | 1800 | 85.83 |
02:42 ET | 673 | 85.884 |
02:44 ET | 1216 | 85.835 |
02:45 ET | 1171 | 85.77 |
02:47 ET | 2535 | 85.86 |
02:49 ET | 5990 | 86.015 |
02:51 ET | 600 | 85.83 |
02:54 ET | 1107 | 85.975 |
02:56 ET | 1509 | 85.9 |
02:58 ET | 2515 | 85.97 |
03:00 ET | 4839 | 85.945 |
03:02 ET | 15040 | 86.12 |
03:03 ET | 515 | 85.95 |
03:05 ET | 600 | 85.87 |
03:07 ET | 1338 | 85.75 |
03:09 ET | 700 | 85.64 |
03:12 ET | 4390 | 85.91 |
03:14 ET | 2071 | 86.19 |
03:16 ET | 2479 | 86.02 |
03:18 ET | 1524 | 86.165 |
03:20 ET | 1100 | 86 |
03:21 ET | 1700 | 86.405 |
03:23 ET | 4954 | 86.6375 |
03:25 ET | 2472 | 86.32 |
03:27 ET | 1257 | 86.23 |
03:30 ET | 400 | 86.25 |
03:32 ET | 16378 | 86.43 |
03:34 ET | 3327 | 86.78 |
03:36 ET | 4875 | 86.83 |
03:38 ET | 2700 | 86.905 |
03:39 ET | 2425 | 86.905 |
03:41 ET | 7424 | 86.72 |
03:43 ET | 4300 | 86.685 |
03:45 ET | 4175 | 86.83 |
03:48 ET | 4165 | 86.77 |
03:50 ET | 4682 | 86.825 |
03:52 ET | 10202 | 86.97 |
03:54 ET | 5474 | 86.73 |
03:56 ET | 10437 | 86.77 |
03:57 ET | 10548 | 86.775 |
03:59 ET | 488772 | 86.61 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arcellx Inc | 4.7B | -82.4x | --- |
ADMA Biologics Inc | 4.7B | 142.1x | --- |
Krystal Biotech Inc | 5.3B | 50.4x | --- |
BridgeBio Pharma Inc | 5.0B | -10.1x | --- |
Crinetics Pharmaceuticals Inc | 4.3B | -14.1x | --- |
Immunovant Inc | 4.3B | -15.3x | --- |
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7B |
---|---|
Revenue (TTM) | $144.7M |
Shares Outstanding | 53.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.05 |
Book Value | $9.28 |
P/E Ratio | -82.4x |
Price/Sales (TTM) | 32.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -55.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.